Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients

Completed · Phase 1/Phase 2

Conditions studied: Ovarian Epithelial Cancer Stage III, Stage IV Ovarian Cancer, Stage IV Breast Cancer

In brief

The purpose of this study is to determine the effectiveness, safety, tolerability and best dose of Lapatinib (GW572016) in combination with carboplatin and paclitaxel.

Key facts

Study ID

NCT00316407

Run by

Swedish Medical Center

People needed

30

Starts

2005-08-01

Expected to finish

2009-11-01

Last updated by the study team

2011-02-18

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Relapsed (Stage III or IV) ovarian, primary peritoneal, fallopian tube carcinoma patients.
• Stage IV metastatic breast cancer patients who have failed no more than four previous chemotherapies for Stage IV disease.
• Ability to swallow and retain oral medications.
• Measurable disease

You may not qualify if…

• Treatment with previous weekly carboplatin and paclitaxel.
• No prior treatment with erbB targeting therapies such as erlotinib, gefitinib and cetuximab.
• No concomitant requirement for medication classification as CYP3A4 inducers or inhibitors.

Where it is running

• University of New Mexico Cancer Center — Albuquerque, New Mexico, United States
• Swedish Medical Center Cancer Institute — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.